Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National MedicinesSHSE:600511 -0.04%90 FCF Margin % is 7.10% as of Jun. 2026, which is 111% above its 10-year median of 3.37. GuruFocus rates SHSE:600511 with a GF Score™ of 90/100 and a GF Value™ of ¥32.09 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 118 Medical Distribution companies, China National Medicines ranks better than 61.02% on this metric.
The historical rank and industry rank for China National Medicines's FCF Margin % or its related term are showing as below:
SHSE:600511'
s FCF Margin % Range Over the Past 10 Years
Min: 1.5 Med: 3.37 Max: 5.19
Current: 1.5
During the past 13 years, the highest FCF Margin % of China National Medicines was 5.19%. The lowest was 1.50%. And the median was 3.37%.
SHSE:600511's FCF Margin % is ranked better than 61.02% of 118
companies
in the Medical Distribution industry
Industry Median: 0.605
vs SHSE:600511: 1.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600511 vs MCK, COR, CAH: FCF Margin % Comparison
For the Medical Distribution subindustry, China National Medicines's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Medicines FCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Medicines's FCF Margin % distribution charts can be found below:
* The bar in red indicates where China National Medicines's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Medicines (SHSE:600511) has a FCF Margin % of 7.10% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on China National Medicines and its competitors. This is 111% above median its historical median of 3.37. Over the past decade, China National Medicines' FCF Margin % has ranged from 1.50 to 5.19. According to the industry distribution chart, China National Medicines ranks #46 out of 118 companies in the Medical Distribution industry, placing it in the top 39%.
Is China National Medicines' FCF Margin % too high?
China National Medicines' current FCF Margin % of 7.10% is 111% above median its 10-year median of 3.37. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 5.19. The Medical Distribution industry median FCF Margin % is 0.61. China National Medicines' value of 7.10% is 1073.6% above this industry median. Based on the distribution chart, China National Medicines ranks #46 out of 118 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, China National Medicines has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' FCF Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China National Medicines ranks #46 out of 118 companies for FCF Margin %. This puts China National Medicines in the upper half of its industry. The industry median FCF Margin % is 0.61. China National Medicines' value of 7.10% is 1073.6% above this benchmark. Historically, China National Medicines' own FCF Margin % has ranged from 1.50 to 5.19 over the past decade. While the company's 10-year median is 3.37 vs. the industry median of 0.61, China National Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Distribution company?
The median FCF Margin % among Medical Distribution companies is 0.61, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Medicines's current FCF Margin % of 7.10% is 1073.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on China National Medicines and its competitors. For the Medical Distribution industry, the median FCF Margin % is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Medicines's current FCF Margin % is 7.10%, which is 111% above median its own 10-year median of 3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.09, compared to a current price of ¥26.77 — trading 16.6% below its estimated fair value. The current FCF Margin % is 7.10%, which is 111% above median its 10-year median of 3.37 and 1073.6% above the Medical Distribution industry median of 0.61. China National Medicines' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current FCF Margin % is 7.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Medicines (SHSE:600511) Overvalued in 2026?
Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued.
The current stock price of ¥26.77 is trading 16.6% below its estimated GF Value™ of ¥32.09.
GuruFocus considers China National Medicines to be Modestly Undervalued.
Key valuation signals for SHSE:600511:
FCF Margin %: 7.10% (111% above median its 10-year median of 3.37)
GF Value™: ¥32.09 vs. price of ¥26.77 (16.6% below fair value)
Industry Position: 1073.6% above the Medical Distribution median (#46 of 118)
No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
90GF Score
Get the complete analysis for SHSE:600511
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600511 has been successfully added to your 
